Drug profile · INN
elagolix sodium,estradiol,norethindrone acetate
ORIAHNN (COPACKAGED)
elagolix sodium,estradiol,norethindrone acetate (ORIAHNN (COPACKAGED)) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
Drug details — elagolix sodium,estradiol,norethindrone acetate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 3
- Programs
- 1
- Data quality
- 0.84
Quick answer
elagolix sodium,estradiol,norethindrone acetate (ORIAHNN (COPACKAGED)) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related patents
-
US 12083227
Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
granted -
US 11459305
Processes for the preparation of uracil derivatives
granted -
US 7419983
Gonadotropin-releasing hormone receptor antagonists and methods related thereto
granted
Frequently asked questions
What is elagolix sodium,estradiol,norethindrone acetate?
elagolix sodium,estradiol,norethindrone acetate (ORIAHNN (COPACKAGED)) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for elagolix sodium,estradiol,norethindrone acetate?
ORIAHNN (COPACKAGED) is a marketed brand name for elagolix sodium,estradiol,norethindrone acetate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of elagolix sodium,estradiol,norethindrone acetate?
elagolix sodium,estradiol,norethindrone acetate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.